Michael Kishbauch Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kishbauch CATB stock SEC Form 4 insiders trading

Michael has made over 6 trades of the Astria Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 495,812 units of CATB stock worth $1,740,300 on 15 August 2014.

The largest trade he's ever made was exercising 495,812 units of Astria Therapeutics Inc stock on 15 August 2014 worth over $1,740,300. On average, Michael trades about 35,868 units every 33 days since 2006. As of 15 August 2014 he still owns at least 54,687 units of Astria Therapeutics Inc stock.

You can see the complete history of Mr. Kishbauch stock trades at the bottom of the page.

Michael Kishbauch biography

Michael D. Kishbauch serves as Independent Director of the Company. Mr. Kishbauch previously served as President and Chief Executive Officer of Achillion Pharmaceuticals, a publicly held biopharmaceutical company, from July 2004 until his retirement in September 2013. Prior to that, he founded and, from 1996 to 2004, served as President and Chief Executive Officer of OraPharma, a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson & Johnson in 2003. Mr. Kishbauch also held senior management positions with MedImmune, Inc., a biotechnology company, from 1992 to 1995. Mr. Kishbauch formerly served as a director of Achillion Pharmaceuticals, Inc., a biotechnology company, from July 2004 through January 2020, Progenics Pharmaceuticals, Inc., a biopharmaceutical company, from 2013 through 2019 and TetraLogic Pharmaceuticals Corporation from 2014 through 2016. Mr. Kishbauch holds an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.

What is the salary of Michael Kishbauch?

As the Independent Director of Astria Therapeutics Inc, the total compensation of Michael Kishbauch at Astria Therapeutics Inc is $82,400. There are 4 executives at Astria Therapeutics Inc getting paid more, with Jill Milne having the highest compensation of $1,032,800.

How old is Michael Kishbauch?

Michael Kishbauch is 71, he's been the Independent Director of Astria Therapeutics Inc since 2016. There are no older and 10 younger executives at Astria Therapeutics Inc.

What's Michael Kishbauch's mailing address?

Michael's mailing address filed with the SEC is C/O CATABASIS PHARMACEUTICALS, INC.,, 100 HIGH STREET, FLOOR 28, BOSTON,, MA, 02110.

Insiders trading at Astria Therapeutics Inc

Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos et Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.

What does Astria Therapeutics Inc do?

Astria Therapeutics Inc executives and stock owners

Astria Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jill Milne,
  President, Chief Executive Officer, Co-Founder, Director
• Joanne Donovan,
  Chief Medical Officer
• Andrew Nichols,
  Chief Scientific Officer
• Kenneth Bate,
  Independent Chairman of the Board
• Michael Kishbauch,
  Independent Director
• Gregg Lapointe,
  Independent Director
• Burt Adelman,
  Independent Director
• Hugh Cole,
  Independent Director
• Joanne Beck,
  Independent Director
• Andrew Komjathy,
  Chief Commercial Officer
• Benjamin Harshbarger,
  Senior Vice President, General Counsel
• Noah Clauser,
  Chief Financial Officer
• Andrea Matthews,
  IR Contact Officer
• Rick Modi,
  Chief Business Officer
• Jean George,
  Director
• V, Llcsv Life Sciences Fund...,
  
• Ron Laufer,
  Director
• Michael Jay Ross,
  Director
• Michael Jirousek,
  Chief Scientific Officer
• Lifesciences Ii, L.P.Clarus...,
  
• Ian C. Sanderson,
  Chief Financial Officer
• Ventures, Inc. Med Immune,
  10% owner
• Nicholas Galakatos,
  Director
• Edward K. Hibben,
  Chief Business Officer
• Fred Callori,
  Director
• Jonathan Violin,
  Director
• Deirdre A. Cunnane,
  Chief Legal Officer
• Advisors Llcperceptive Life...,